Amicus Therapeutics Inc (FRA:AM6) Stock News, Headlines & Updates
Amicus Therapeutics Inc Stock News from GuruFocus
- 1
Jul 21, 2025
Amicus Therapeutics Inc (FOLD) Announces Upcoming Q2 2025 Financial Results Conference Call | FOLD stock news
GuruFocus News • 6:08am
Amicus Therapeutics to Announce Second Quarter 2025 Financial Results on July 31, 2025
Marketwired • 6:00am
Jul 17, 2025
Amicus Therapeutics (FOLD) Stock Rises After Morgan Stanley Upgrade
GuruFocus News • 2:57pm
Amicus Therapeutics (FOLD) Upgraded by Morgan Stanley: Price Target Raised | FOLD Stock News
GuruFocus News • 7:02am
Jul 16, 2025
Amicus (FOLD) Receives Upgrade from Morgan Stanley with Increased Price Target | FOLD Stock News
GuruFocus News • 6:15pm
Amicus (FOLD) Stock Receives Upgrade from Morgan Stanley | FOLD Stock News
GuruFocus News • 5:45pm
Jul 10, 2025
SHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term FOLD Investors to Contact the Firm
PRNewswire • 8:00am
Jun 25, 2025
Amicus (FOLD) Gains Approval for Pompe Disease Treatment in Japan | FOLD Stock News
GuruFocus News • 6:35am
Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) in Japan | FOLD Stock News
GuruFocus News • 6:21am
Amicus Therapeutics Inc (FOLD) Gains Approval for Pombiliti® + Opfolda® in Japan | FOLD stock news
GuruFocus News • 6:07am
Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) in Japan
Marketwired • 6:00am
Jun 03, 2025
Amicus Therapeutics Inc (FOLD) Publishes Promising Post-Hoc Analysis Results for Pompe Disease Treatment | FOLD stock news
GuruFocus News • 7:04am
Amicus (FOLD) Reports Positive Findings from PROPEL Study in Pompe Disease | FOLD Stock News
GuruFocus News • 6:31am
New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve | FOLD Stock News
GuruFocus News • 6:21am
New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve
Marketwired • 6:00am
May 30, 2025
Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025 | FOLD Stock News
GuruFocus News • 6:19am
Amicus Therapeutics Inc (FOLD) Announces Participation in Upcoming Investor Conferences | FOLD stock news
GuruFocus News • 6:01am
Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025
Marketwired • 6:00am
May 07, 2025
Amicus Therapeutics to Present at the Bank of America 2025 Health Care Conference
Marketwired • 6:00am
May 02, 2025
UBS Raises Price Target for Amicus Therapeutics (FOLD) to $22, Maintains Buy Rating | FOLD Stock News
GuruFocus News • 6:01pm
Amicus Therapeutics (FOLD) Target Price Lowered by Goldman Sachs | FOLD Stock News
GuruFocus News • 12:34pm
UBS Boosts Amicus (FOLD) Price Target Despite Revised Pompe Disease Outlook | FOLD Stock News
GuruFocus News • 8:47am
May 01, 2025
Amicus (FOLD) Shows Strong Revenue Growth Amid Recent Quarter Challenges | FOLD Stock News
GuruFocus News • 6:18am
Amicus Therapeutics Inc Reports Q1 2025 Earnings: EPS of -$0.07 Misses Estimates, Revenue at $125.2 Million Below Expectations
GuruFocus News • 6:14am
Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates
Marketwired • 6:00am
Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States
Marketwired • 7:00pm
Apr 30, 2025
- 1
Show
Entries
Headlines
Total 0- 1
No recent news